Trial Profile
Phase II study of antineoplastons A10 and AS2-1 in patients with non-Hodgkin's lymphoma
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 25 Jan 2021
Price :
$35
*
At a glance
- Drugs Antineoplaston A10/antineoplaston AS2-1 (Primary)
- Indications Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- 30 Jan 2018 Status changed from active, no longer recruiting to discontinued due to slow accrual.
- 26 Oct 2008 Planned end date changed from 1 Jan 2008 to 1 Feb 2007 as reported by ClinicalTrials.gov.
- 18 Apr 2008 Status change from recruiting to in progress, according to clinicaltrials.gov.